

Index

A

- Advanced glycation end products (AGEs), 30
- Alzheimer's disease (AD), 2, 117, 118
 - clinical diagnosis, 94–95
 - incidence, 93
 - late onset/sporadic AD (LOAD), 93
 - management, 95
 - pathogenesis
 - amyloid β -peptide, 96
 - brain amyloid accumulation, 97
 - cytokines, 98
 - genetic polymorphisms, 98
 - inflammatory hypothesis, 97
 - low-density lipoprotein receptor-related protein 1 (LRP1), 97
 - peripheral inflammation, 98
 - peripheral inflammatory mechanisms, 99–100
 - senile plaques, 98
 - and periodontitis
 - bacteremia, 100
 - cytokines and LPS, 101
 - infection-induced effects, 101
 - monocytes, 101
 - RAGE production, 102
 - prevalence, 93
- American Academy of Periodontology (AAP), 6
- American Association of Clinical Endocrinologists (AACE), 27
- Aspiration pneumonia
 - oral care
 - chlorhexidine (CHX), 87
 - edentulous patients, 88
 - oral interventions, 87
 - oral health
 - nursing home residents, 87
 - oral microflora, 86
- Atherosclerosis, 2, 117, 118

- Atherosclerotic vascular diseases (ASVD)
 - ASVD and periodontitis, 43–44
 - biologic mechanisms, 44
 - Framingham risk, 40
 - healthy diet and exercise plan, 40
 - hypercholesterolemia, 40
 - infection, 45–46
 - inflammation, 46–47
 - atheroma enlargement, 42
 - cholesterol, 41, 42
 - C-reactive protein (CRP), 43
 - endothelial cells, 41
 - endothelial dysfunction, 41
 - extracellular matrix deposition, 42–43
 - foam cell formation, 42
 - high-density lipoproteins (HDL), 42
 - hyperlipidemia, 41
 - intracellular non-degraded
 - cholesterol, 42
 - lipid accumulation, 41
 - low-density lipoprotein (LDL), 42
 - matrix metalloproteinases (MMPs), 43
 - pro-inflammatory mediators, 41
 - smooth muscle cell proliferation, 41, 42
 - thrombosis and/or intraplaque
 - hemorrhage, 42
 - thrombus formation (embolism), 43
 - molecular mimicry, 46
 - mortality, 39
 - periodontal therapy, 47–48
 - prevention, 39
 - risk factor, 47
 - vascular occlusion, 39

C

- Carotid intima-media thickness (CIMT), 48
- Centers for Disease Control (CDC), 6
- Chlorhexidine (CHX), 87

- Chronic kidney diseases (CKD)
- end-stage renal disease (ESRD)
 - causes, 55
 - incident counts and adjusted rates, 56
 - incident rate, 55
 - medical complexity, 54
 - mortality, 54
 - periodontitis
 - management, for CKD patient, 61–62
 - prevalence and severity, 59–60
 - risk factor, 60–61
 - renal hemodialysis, 54
 - and renal replacement therapies
 - donor kidneys, 58
 - glomerular filtration rate (GFR), 54
 - heparin, 55
 - histocompatibility leukocyte antigen (HLA) complexes, 57
 - immune suppression, 58
 - incident and prevalent patient counts, 56
 - patient's circulatory system, 55
 - peritoneal dialysis, 55
 - renal hemodialysis, 55, 56
 - transplant survival rates, 58
 - systemic inflammation, 58–59
- D**
- Diabetes mellitus
- advanced glycation end products (AGEs), 30
 - AGE-RAGE interactions, 28
 - bacterial burden, 30
 - bacterial infections, 31
 - CARE study, 27
 - categories, 24
 - chronic periodontal inflammation, 30
 - classic signs and symptoms, 22
 - classification, 21
 - clinical management
 - dental considerations, 33
 - medical considerations, 33–34
 - complication, 25
 - criteria, 23, 24
 - cytokine activation, 25
 - degenerative vascular changes, 30
 - Diabetes Control and Complications Trials (DCCT), 26
 - disability and death, 27
 - DNA analysis, 28
 - epidemiologic studies, 29
 - FPG, 23
 - gestational diabetes mellitus (GDM), 21
 - HbA1c, 23, 26
 - high-sensitivity C-reactive protein (hsCRP)
 - levels, 27
 - hyperglycemia, 25
 - insulin resistance, 28
 - insulin therapy, 22
 - ketoacidosis, 21
 - ketones, 21
 - kidney dysfunction, 31
 - long-term complications, 20
 - matrix metalloproteinases (MMPs), 30
 - metabolic syndrome, 24
 - microvascular and macrovascular
 - complications, 26
 - monocytic hypersecretory phenotype, 30
 - motor and sensory nerve conduction
 - velocity, 26
 - multivariate risk analysis, 29
 - neuropathy, 26
 - NHANES III database, 27
 - NHANES III study, 29
 - ominous octet, 22
 - oral changes, 27
 - oral inflammation, 30
 - osmotic and oxidative stress, 25
 - pancreatic autoimmune β -cell
 - destruction, 21
 - pathophysiological abnormalities, 23
 - periodontal wound healing, 29
 - physical activity and dietary changes, 20
 - prevalence, 20
 - proteinuria, 31
 - retinopathy, 29
 - screening, 22–24
 - self-monitoring of blood glucose (SMBG), 26
 - serum CRP levels, 28
 - therapeutic strategies, 31–32
 - TNF- α , 31
- E**
- Endothelial dysfunction, 48
- End-stage renal disease (ESRD), 31
- causes, 55
 - incident counts and adjusted rates, 56
 - incident rate, 55
- F**
- Fasting plasma glucose (FPG), 23
- Flurbiprofen, 16

G

- Genome-wide studies, 9–10
- Glucosyltransferase-6 gene, 10
- Gram-negative anaerobic species, 2, 117
- Gram-negative assacharolytic anaerobic bacteria, 13
- Gram-negative cocci and rods, 11

H

- High-density lipoproteins (HDL), 42
- Hypercholesterolemia, 40

I

- Insulin Resistance Atherosclerosis Study (IRAS), 28

L

- Low-density lipoprotein (LDL), 42

M

- Matrix metalloproteinases (MMPs), 16, 43
- Metabolic syndrome, 24

N

- Neutrophils, 14
- Nod receptors, 12
- Non-steroidal anti-inflammatory medications, 16
- Nursing-home associated pneumonia (NHAP), 84

O

- Oral health and pneumonia
 - community-acquired pneumonia
 - antibiotics, 82
 - bacterial pneumonia, 81
 - chest radiography, 82
 - clinical symptoms, 82
 - etiologic agents, 82
 - immunosuppression, 81
 - morbidity and mortality, 81
 - risk factor, 82
 - treatment, 82
 - HAP and HCAP
 - aspiration pneumonia, 84, 86–88

- nursing-home associated pneumonia (NHAP), 84
- pathogenesis, 84–86

P

- Periodontal diseases, 1–3
 - classification and prevalence, 6–7
 - dental biofilm
 - arachidonic acid cascade, 12
 - asaccharolytic bacteria, 11
 - bone resorption pathways, 13
 - exopolysaccharide matrix, 10
 - F. nucleatum* species, 11
 - gingival epithelial cells, 12
 - gingival epithelium, 13
 - Gram-negative cocci and rods, 11
 - Gram-positive aerobic cocci, 11
 - Gram-positive aerobic saccharolytic bacteria, 11
 - growth factors and metabolites, 10
 - host matrix metalloproteinase, 13
 - metabolic and nutrient requirements, 11
 - Nod receptors, 12
 - Peyer's patches, 12
 - salivary and bacterial proteins, 11
 - scaffold, 10
 - toll-like receptors (TLRs), 12
 - host subversion
 - bystander bacteria, 14
 - Gram-negative assacharolytic anaerobic bacteria, 13
 - matrix metallo-proteinases, 14
 - neutrophils, role of, 14
 - peptides and amino acid, 13
 - P. gingivalis*, 14
 - management, 15–17
 - pathogenesis, 2
 - susceptibility
 - chronic adult periodontitis, 8
 - clinical significance, 10
 - DNA sequence, 9
 - gene polymorphisms, 9
 - genetic component, 8
 - genome-wide studies, 9–10
 - gingival inflammation, 9
 - gingival vasoconstriction, 8
 - glucosyltransferase-6 gene, 10
 - risk factors, 7
 - single nucleotide polymorphisms, 9
 - smoking, 7–8

- Periostat®, 16
Peyer's patches, 12
Pneumonia, 117, 118
Preterm labor (PTL), 118
 alcohol consumption, 70
 clinical trials, 70
 concomitant medication, 75
 dental plaque, 71
 drug use, 70
 genetic abnormalities, 76
 gestational age, 72
 gum inflammation, 75
 inflammation and gum swelling, 71
 inflammatory gum disease, 68
 inflammatory marker C-reactive protein, 75
 inflammatory markers, 68
 low birth weight incidence, 71
 meta-analysis, 69–70, 73–74
 microbial infections, 68
 nonalcoholic antiseptic mouthwash, 72
 observational studies, 69
 oral hygiene, 72
 outcome measures, 72
 progesterone treatment, 75
 smoking, 70
 subject selection criteria, 75
 treatment, 72, 75
 US study, 71
- R**
Retinopathy, 29
Rheumatoid arthritis (RA), 2, 117, 118
 environmental risk factors, 107
 host predisposition and risk factors, 107
 microbiome, 107
 periodontitis and subgingival microbiome
 antibiotics and DMARD
 treatments, 111
 anti-TNF medications, 109
 bone erosion, 108
 new-onset rheumatoid arthritis (NORA)
 patients, 109
 peptidylarginine deiminase (PAD), 109
 scaling and root planing (SRP), 112
 TNF- α , 107, 110
 TNFis, 110–111
- S**
Scaling and root planing (SRP), 112
Self-monitoring of blood glucose (SMBG), 26
Single nucleotide polymorphisms, 9
- T**
Toll-like receptors (TLRs), 12
Type 2 diabetes mellitus, 2, 117
- U**
United Kingdom Prospective Diabetes Study (UKPDS), 26
United States National Health and Nutrition Examination Survey (NHANES), 6